Ann: Annual Financial Results Presentation, page-133

Exactly, he makes no sense for the reality of where MSB are with the FDA. He doesn’t want to face the current state and latest movements of FDA that clearly are now supportive of MSB and understanding their data and wanted MSB’s BLA resubmission and faster than we all thought.

Quite twisted the daily rhetoric from some of these naysayers just because they have either personally lost money or are personally invested in a rival company but willing to trash a company who’s core mandate is to save lives where there is clinical unmet need.

They should be ashamed as their posts are not about education but purely about personal selfishness.